secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001193125-25-188078
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck closes up to $103M private placement, appoints two new directors, cash runway into 2029
--------------------------------------------------------------------------------

- Closed private placement of up to ~$103M led by OrbiMed; net proceeds to fund SL-325 through Phase 2 trials.
- Pro forma cash, assuming full warrant exercise, expected to fund operations into 2029.
- Appointed Dr. Daniel Baker (independent director) and Dr. Mona Ashiya (OrbiMed designee) to Board.
- Directors Tyler Brous, Carrie Brownstein, Michael Lee, Kate Sasser resigned upon closing.
- SL-325 (DR3 blocking antibody) IND cleared; Phase 1 trial to start this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000119312525188078/0001193125-25-188078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000119312525188078/d95844d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-188078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer